BiotechTube

Camrelizumab + Camrelizumanb plus TPF

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Oral Squamous Cell Carcinoma

Conditions

Oral Squamous Cell Carcinoma

Trial Timeline

Mar 22, 2021 → Aug 10, 2024

NCT ID
NCT04649476

About Camrelizumab + Camrelizumanb plus TPF

Camrelizumab + Camrelizumanb plus TPF is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Oral Squamous Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04649476. Target conditions include Oral Squamous Cell Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04649476Phase 2Completed

Competing Products

20 competing products in Oral Squamous Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
AL001 + Placebo + Open label - AL001AlectorPhase 3
69
AL001AlectorPhase 2
44
AG013OragenicsPhase 2
44
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
44
Micafungin + FluconazoleAstellas PharmaPhase 3
77
micafungin + caspofunginAstellas PharmaPhase 3
77
Erlotinib + PlaceboAstellas PharmaPhase 3
77
AmifostineSun PharmaceuticalApproved
85
exenatide + Other antidiabetic therapiesEli LillyPre-clinical
23
Teriparatide 20 mcgEli LillyPhase 3
77
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional PrednisoneEli LillyPhase 1/2
41
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
52
tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved
85
Essential oils + 0.2% chlorhexidine + Sterile waterJohnson & JohnsonApproved
85
galantamine hydrobromideJohnson & JohnsonPhase 2
52
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
77
Camrelizumab plus TP + TPJiangsu Hengrui MedicinePhase 3
77
AZD1981 + Neovletta 21/28 + Placebo AZD1981AstraZenecaPhase 1
33
DurvalumabAstraZenecaPhase 1/2
41
fostamatinib + Microgynon® 30 (Oral contraceptive) + PlaceboAstraZenecaPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85